HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masayuki Shibasaki Selected Research

YM 440

11/2006YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
8/2006The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats.
3/2003Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
7/2002Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masayuki Shibasaki Research Topics

Disease

21Type 2 Diabetes Mellitus (MODY)
03/2014 - 11/2006
8Hyperglycemia
03/2014 - 03/2003
8Glucose Intolerance
09/2013 - 07/2002
8Hypertrophy
01/2012 - 01/2006
7Insulin Resistance
09/2013 - 06/2006
6Neoplasms (Cancer)
10/2020 - 11/2005
5Hypoglycemia (Reactive Hypoglycemia)
04/2012 - 05/2008
5Hyperplasia
01/2012 - 01/2006
4Body Weight (Weight, Body)
03/2014 - 07/2002
4Obesity
09/2013 - 06/2006
3Inflammation (Inflammations)
07/2014 - 06/2010
3Diabetic Nephropathies (Diabetic Nephropathy)
04/2011 - 11/2006
2Neoplasm Metastasis (Metastasis)
10/2020 - 06/2015
2Hemorrhage
01/2017 - 11/2005
2Albuminuria
07/2014 - 11/2006
2Hyperlipidemias (Hyperlipidemia)
09/2013 - 11/2006
2Prostatic Neoplasms (Prostate Cancer)
11/2005 - 11/2005
1Abdominal Pain (Pain, Abdominal)
01/2017
1Splenomegaly
01/2017
1Pathologic Constriction (Stenosis)
01/2016
1Brain Neoplasms (Brain Tumor)
06/2015
1Breast Neoplasms (Breast Cancer)
06/2015
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/2014
1Weight Loss (Weight Reduction)
03/2014
1Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2013
1Hyperinsulinism (Hyperinsulinemia)
09/2013
1Pain (Aches)
04/2011
1Wounds and Injuries (Trauma)
04/2011
1Hypersensitivity (Allergy)
04/2011
1Inappropriate ADH Syndrome (SIADH)
01/2011
1Hypertriglyceridemia
10/2010
1Cholestasis
06/2010
1Neuralgia (Stump Neuralgia)
06/2010
1Hyperalgesia
06/2010

Drug/Important Bio-Agent (IBA)

12Glucose (Dextrose)FDA LinkGeneric
09/2013 - 07/2002
9Hypoglycemic Agents (Hypoglycemics)IBA
04/2012 - 08/2006
9Vasopressins (Vasopressin)IBA
01/2012 - 01/2006
8Insulin (Novolin)FDA Link
09/2013 - 08/2006
6Streptozocin (Streptozotocin)FDA Link
07/2014 - 12/2008
5ipragliflozinIBA
07/2014 - 01/2012
5Niacinamide (Nicotinamide)FDA LinkGeneric
09/2013 - 12/2008
54- fluoro- 1- (((4- methyl- 1- (methylsulfonyl)piperidin- 4- yl)amino)acetyl)pyrrolidine- 2- carbonitrileIBA
03/2009 - 05/2008
4Dipeptidyl-Peptidase IV InhibitorsIBA
01/2014 - 07/2008
4YM 440IBA
11/2006 - 07/2002
3Sodium-Glucose Transport ProteinsIBA
07/2014 - 01/2012
3Blood Glucose (Blood Sugar)IBA
09/2013 - 02/2009
3Collagen Type IV (Type IV Collagen)IBA
01/2012 - 02/2008
34'- (4,4- difluoro- 5- (2- oxo- 2- (4- piperidinopiperidino)ethylidene)- 2,3,4,5- tetrahydro- 1H- 1- benzoazepine- 1- carbonyl)- 2- methyl- 3- furanilideIBA
06/2007 - 01/2006
2Hormones (Hormone)IBA
06/2015 - 04/2011
2G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
02/2013 - 10/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2011 - 03/2011
2Triglycerides (Triacylglycerol)IBA
10/2010 - 02/2009
2Biological ProductsIBA
06/2010 - 11/2005
2EnzymesIBA
05/2008 - 04/2008
2ImmunosorbentsIBA
05/2008 - 04/2008
2LigandsIBA
06/2006 - 11/2005
2PPAR gammaIBA
06/2006 - 03/2003
2Paclitaxel (Taxol)FDA LinkGeneric
03/2006 - 11/2005
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
03/2006 - 11/2005
2Proteins (Proteins, Gene)FDA Link
01/2006 - 11/2005
2Androgen Receptors (Androgen Receptor)IBA
11/2005 - 11/2005
2AndrogensIBA
11/2005 - 11/2005
1Cetuximab (Erbitux)FDA Link
10/2020
1Capecitabine (Xeloda)FDA Link
06/2015
1Lapatinib (GW572016)FDA Link
06/2015
1Therapeutic UsesIBA
09/2013
1bis(2- ((4- ((4'- (2- hydroxyethoxy)- 2'- methyl(1,1'- biphenyl)- 3- yl)methoxy)phenyl)methyl)- 3,5- dioxo- 1,2,4- oxadiazolidine)IBA
09/2013
1Leucine (L-Leucine)FDA Link
01/2012
1ThymidineIBA
01/2012
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
04/2011
1Insulin-Like Growth Factor I (IGF-1)IBA
04/2011
1Insulin-Like PeptidesIBA
04/2011
1Sitagliptin Phosphate (Januvia)FDA Link
03/2011
1Rosiglitazone (Avandia)FDA Link
03/2011
1SecretagoguesIBA
03/2011
12- (4- bromophenyl)- 6- methyl- N- (2- (1- oxidopyridin- 3- yl)ethyl)pyrimidin- 4- amineIBA
11/2010
1Glyburide (Glibenclamide)FDA LinkGeneric
11/2010
12- cyclopentyl- N- (2,4- dichloro- 3- ((isoquinolin- 5- yloxy)methyl)phenyl)- N- methylacetamideIBA
10/2010
1AS 1907417IBA
10/2010
12- (2- (4- bromophenyl)- 6- methylpyrimidin- 4- yl)aminoethanolIBA
09/2010
1HMGB ProteinsIBA
06/2010
1CytokinesIBA
06/2010
1Neutralizing AntibodiesIBA
06/2010
1Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
02/2009
1Fatty Acids (Saturated Fatty Acids)IBA
02/2009
1LipidsIBA
02/2009
1CholesterolIBA
02/2009
1Hemoglobin AIBA
02/2009
1Glucagon-Like Peptide 1 (GLP 1)IBA
01/2009
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2009
1Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA
01/2009

Therapy/Procedure

6Therapeutics
06/2015 - 11/2005
2Anesthesia
01/2016 - 11/2005
2Oral Administration
08/2013 - 03/2006
1Induction Chemotherapy
10/2020
1Splenectomy
01/2017
1Tracheostomy
01/2016
1CAP protocol 2
06/2015
1Hepatectomy
06/2010
1Glycemic Control
03/2009